Emiliem, Inc. - Molecularly Targeted Oncology Therapeutics, Multi-Kinase Inhibitor

Emiliem, Inc. Press Release - February 14, 2007

Sucha Sudarsanam, CSO, to present at IBC Life Sciences conference on Partnering and Outsourcing Models in Biology and Pre-clinical R&D, February 21, 2007, San Diego

Sucha Sudarsanam, CSO of Emiliem, Inc. will present "Sourcing and Integrating Drug Discovery Services and Collaborative Drug Discovery Research: Perspectives from a Small Company". Sudarsanam and J.B. Gupta, SVP, Collaborative Research, GVK Biosciences will discuss the opportunities and challenges of collaborative drug discovery research undertaken in India, using the Emiliem/GVK model as an illustrative example.

More information on Sucha Sudarsanam can be found on www.emiliem.com

About Us

Emiliem, Inc. is a developmental-stage biotechnology company focused on the discovery and development of molecularly targeted oncology drugs. The Company is creating novel oncology therapeutics by identifying relevant multiple kinase targets in cancer and designing this multi-selectivity into each new lead compound. Emiliem's approach to developing targeted drugs includes the ability to identify proprietary biomarkers. Coupling drug discovery with biomarker identification and implementation increases the likelihood of achieving clinical trial endpoints and receiving approval to market these innovative drug candidates.

The Company is headquartered in Emeryville, California.



	HOME \| ABOUT \| CORPORATE \| BUSINESS MODEL\| PIPELINE \| PRESS \| NEWS \| CONTACT

	Emiliem, Inc. Press Release - February 14, 2007 Sucha Sudarsanam, CSO, to present at IBC Life Sciences conference on Partnering and Outsourcing Models in Biology and Pre-clinical R&D, February 21, 2007, San Diego Sucha Sudarsanam, CSO of Emiliem, Inc. will present "Sourcing and Integrating Drug Discovery Services and Collaborative Drug Discovery Research: Perspectives from a Small Company". Sudarsanam and J.B. Gupta, SVP, Collaborative Research, GVK Biosciences will discuss the opportunities and challenges of collaborative drug discovery research undertaken in India, using the Emiliem/GVK model as an illustrative example. More information on Sucha Sudarsanam can be found on www.emiliem.com About Us Emiliem, Inc. is a developmental-stage biotechnology company focused on the discovery and development of molecularly targeted oncology drugs. The Company is creating novel oncology therapeutics by identifying relevant multiple kinase targets in cancer and designing this multi-selectivity into each new lead compound. Emiliem's approach to developing targeted drugs includes the ability to identify proprietary biomarkers. Coupling drug discovery with biomarker identification and implementation increases the likelihood of achieving clinical trial endpoints and receiving approval to market these innovative drug candidates. The Company is headquartered in Emeryville, California.